Company intelligence / Profile preview

Nodus Oncology

Edinburgh, Scotland, United Kingdomnodusoncology.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nodus Oncology develops first-in-class and best-in-class small molecule inhibitors targeting novel DNA damage response mechanisms in cancer. Their lead programs are preclinical, focusing on exploiting synthetic lethality in tumors with specific molecular vulnerabilities. No clinical results have been reported yet; the company’s approach aims to induce replication stress and cell death selectively in cancer cells by inhibiting key DDR proteins such as PARG and NOD1.

Therapeutic areas: Oncology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

2 assets

NODX-010

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Lead Discovery Center, Dortmund, GermanyCumulus Oncology

Beyond the preview

Go deeper on Nodus Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nodus Oncology.

Explore the full profile